Subscribe to our newsletter

Investor Resources

Who We Are

Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform with a data-driven approach. Liminal BioSciences has its registered office in Bellevlle, Ontario and talent hubs in Laval, Quebec, Canada, and Cambridge, UK.

Our common shares are listed for trading on the Nasdaq Market (LMNL).

Stock Quote

GPR84 Antagonist

The GPR84 receptor is primarily expressed in immune cells in addition to multiple organ systems. It plays a key role in the linkage and regulation of the inflammatory and metabolic response, and promotes fibrosis. Learn more.

OXER1 Antagonist 

OXER1 is a GPCR receptor which is mainly expressed ininflammatory cells. OXER1 is highly selective for 5 oxo ETE, one of the most powerful chemo attractants and activators of eosinophils. Learn more.

Recent News
Jan 26, 2023

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued and outstanding common shares of the Company ("Common Shares")...

Jan 19, 2023

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company...

Jan 6, 2023

Closed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024. Plans to divest its remaining non-core assets, to further extend runway. Nominated...

More News

Latest Events
Thursday, November 10, 2022
8:30am - 9:30am EST

Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and...

Wednesday, August 10, 2022
8:30am - 9:30am EDT
Investor Resources